Gastrointestinal<unk>  is frequently associated with gastrointestinal side effects such as dyspepsia, nausea, gastritis, gastroesophageal reflux disease and vomiting. To reduce the severity of these reactions,<unk>  is to be taken after meals. Skin<unk>  is known to cause photosensitivity reactions, rash, pruritus and dry skin. Patients are usually advised to avoid direct exposure to sunlight, including sun lamps, and to use protective clothing and sunscreening agents. Continuing photosensitivity reactions are usually managed by dose adjustment and temporary discontinuation of treatment if required, along with local symptomatic treatment. Hepatic dysfunction<unk>  can increase hepatic enzyme levels, especially those of aspartate transaminase, alanine transaminase and gamma-glutamyl transpeptidase; periodic monitoring of hepatic enzyme levels is required during therapy: once before the initiation of therapy, monthly monitoring until 6 months after initiation of therapy, and 3 monthly thereafter. Extra precaution is required while prescribing the drug in patients with hepatic impairment and in patients who are concomitantly taking a CYP1A2 inhibitor. The drug is contraindicated in patients who have severe hepatic impairment. Dizziness and fatigue Dizziness and fatigue have been reported in patients undergoing<unk>  treatment. Dizziness typically resolves, although patients should know how they react to<unk>  before undertaking activities that need mental alertness or coordination. If severe, dose adjustment or treatment discontinuation may be required. Weight loss Weight loss has been reported in patients treated with<unk> . Doctors should monitor patients’ weight and encourage increased caloric intake if necessary.
Pirfenidone
Lurasidone
Chlortalidone
Methylphenidate
Dexmethylphenidate
Rimonabant
Ethylphenidate
Pirlindole